Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\CTWM2OD1yLkCwNFQ2QCCwTR?= MnzyV2FPT0WU
ES4 NVXafJFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qzbGlEPTB;MD6wNFA3PTNibl2= M1;ie3NCVkeHUh?=
ACHN MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETGc4lKSzVyPUCuNFAxQDh5IH7N MoD1V2FPT0WU
KYSE-510 NV2wXIg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnlTWM2OD1yLkCwNFk4PSCwTR?= MlXqV2FPT0WU
EW-7 NITZSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjneXJKSzVyPUCuNFAzPThibl2= NFLteWRUSU6JRWK=
BFTC-905 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnHeYtEUUN3ME2wMlAxPTF3IH7N MYLTRW5ITVJ?
KE-37 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL2TWM2OD1yLkCwOVYyKG6P MVfTRW5ITVJ?
SBC-5 M4X3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS0TWM2OD1yLkCwOVchdk1? NITVTGVUSU6JRWK=
NKM-1 M{\s[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC1PG1KSzVyPUCuNFA4ODlibl2= MnqyV2FPT0WU
RH-1 M1nYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjXUohKSzVyPUCuNFA4OThibl2= NEjtWYZUSU6JRWK=
ALL-PO NXPZ[YhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHlTWM2OD1yLkCwPFMhdk1? NVjUTokyW0GQR1XS
QIMR-WIL Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfJTWM2OD1yLkCwPFk1KG6P NEfpWmFUSU6JRWK=
A375 NXzjTo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPIUplKSzVyPUCuNFA6QTVibl2= NWGzUG5KW0GQR1XS
SIG-M5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLOfm1KSzVyPUCuNFExPCCwTR?= Ml\xV2FPT0WU
KGN NGLwRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnYTWM2OD1yLkCxNFghdk1? MkP0V2FPT0WU
EW-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkntTWM2OD1yLkCxNVIhdk1? M2DRWHNCVkeHUh?=
NCI-SNU-1 M{f6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj4bo5zUUN3ME2wMlAyPiCwTR?= NF3OTJZUSU6JRWK=
PSN1 M1\YUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHDNXF5UUN3ME2wMlAyPjVibl2= MXzTRW5ITVJ?
HUTU-80 M{DifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMEG2OkBvVQ>? NH3kbIpUSU6JRWK=
EW-16 M3zDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEKzJI5O Mn3TV2FPT0WU
786-0 M3nmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHJRo9KSzVyPUCuNFI{KG6P NGi2PHBUSU6JRWK=
ES1 M4\jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zyZmlEPTB;MD6wNlY5KG6P M1LlWHNCVkeHUh?=
RKO NWrvNndiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vzfWlEPTB;MD6wNlc6KG6P NFrzV|hUSU6JRWK=
ESS-1 NVzkSmplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zsOmlEPTB;MD6wNlg3KG6P Mlr2V2FPT0WU
SK-UT-1 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;kVmlEPTB;MD6wNlk4KG6P MV;TRW5ITVJ?
LB2241-RCC M3:zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInmXHFKSzVyPUCuNFMyQCCwTR?= MmHzV2FPT0WU
CHL-1 NXvSUJI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\BTWM2OD1yLkCzNlQhdk1? M3vmVHNCVkeHUh?=
SW1783 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S2WGlEPTB;MD6wN|M3KG6P Ml\KV2FPT0WU
MEL-JUSO NITROHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPVU2k1UUN3ME2wMlA{QTFibl2= NVm0XJhPW0GQR1XS
HT-29 NGf4elBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HnVmlEPTB;MD6wOFE{KG6P MmTVV2FPT0WU
SNG-M NEXIWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIWyUHpKSzVyPUCuNFQzPSCwTR?= Mki3V2FPT0WU
TE-15 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMES2OEBvVQ>? MmTQV2FPT0WU
HOS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33UVWlEPTB;MD6wOFghdk1? NYD3[GRHW0GQR1XS
BB65-RCC Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TLeGlEPTB;MD6wOVEzKG6P NF75cllUSU6JRWK=
HCE-4 NYnnXFVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rwXmlEPTB;MD6wOVI5KG6P NUnaZVJKW0GQR1XS
MHH-ES-1 NVL1fWxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[1ZWlEPTB;MD6wOVMyKG6P NX\xW2xMW0GQR1XS
RPMI-7951 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEW0NUBvVQ>? MmrPV2FPT0WU
IST-SL2 NIPNNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWyTWM2OD1yLkC1PFQhdk1? NI\B[WhUSU6JRWK=
CMK MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDnTWM2OD1yLkC1PFYhdk1? NFTyeYdUSU6JRWK=
GR-ST MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvZTWM2OD1yLkC1PVUhdk1? NXXC[XVtW0GQR1XS
NALM-6 NF\WV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi2boRwUUN3ME2wMlA3OjJibl2= NUW2fmR{W0GQR1XS
RPMI-6666 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPETWM2OD1yLkC2OVIhdk1? MWfTRW5ITVJ?
LC-2-ad MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwME[1N{BvVQ>? M1j1SnNCVkeHUh?=
ARH-77 NVnQS4RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3aTWM2OD1yLkC3NVEhdk1? NVrrRoZOW0GQR1XS
IST-MEL1 NIPFTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEeyOkBvVQ>? MkTsV2FPT0WU
SW1710 NIfNOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjtToNEUUN3ME2wMlA4PTFibl2= M37xPHNCVkeHUh?=
DEL NIn0R4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLTWoxXUUN3ME2wMlA5QDdibl2= NWDISXk4W0GQR1XS
AGS NXnHbIg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7LTWM2OD1yLkC5NFIhdk1? M2XYdHNCVkeHUh?=
NCI-H2122 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjlTWM2OD1yLkC5OFYhdk1? NIPsOXpUSU6JRWK=
HSC-4 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMUCyJI5O MX3TRW5ITVJ?
AM-38 M{PYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMUKxJI5O M{jwdHNCVkeHUh?=
769-P NHrLSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXBO2pKSzVyPUCuNVI{KG6P M3vnNHNCVkeHUh?=
RT-112 NXnM[I1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XSb2lEPTB;MD6xNlchdk1? MV3TRW5ITVJ?
MCF7 NHe2fItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUiwVol3UUN3ME2wMlE{PiCwTR?= MXrTRW5ITVJ?
IGROV-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jqOWlEPTB;MD6xOFUhdk1? M2HsbnNCVkeHUh?=
OCI-AML2 NXvoUVc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3njU2lEPTB;MD6xOFchdk1? MXHTRW5ITVJ?
NCI-H1299 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV33PHZVUUN3ME2wMlE2PyCwTR?= MWrTRW5ITVJ?
A431 NHfWdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HvZWlEPTB;MD6xPFMhdk1? MnnzV2FPT0WU
SW982 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz0TWM2OD1yLkKxN{BvVQ>? NFXrclNUSU6JRWK=
BB30-HNC NYTYUnpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMkOxJI5O Mly4V2FPT0WU
ACN M1rMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkKyTWM2OD1yLkK0OEBvVQ>? M4\NNnNCVkeHUh?=
647-V NXKxU5lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMkS4JI5O MVrTRW5ITVJ?
SK-PN-DW NYfLXZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvvd5lKSzVyPUCuNlY3KG6P MnHFV2FPT0WU
LCLC-97TM1 NHrlU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMk[3JI5O M2nxPHNCVkeHUh?=
LB1047-RCC NYjhZ3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXuTWM2OD1yLkK2PUBvVQ>? MU\TRW5ITVJ?
A2780 NHr6e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nJNWlEPTB;MD6yO{BvVQ>? Mo[2V2FPT0WU
C-33-A MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMkezJI5O M1LQfHNCVkeHUh?=
NCI-H2228 M2roVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwM{G0JI5O MXLTRW5ITVJ?
TE-5 M1PCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqzUXlsUUN3ME2wMlMyPiCwTR?= M1HFUXNCVkeHUh?=
HC-1 NF:0b5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwM{K3JI5O M12zNXNCVkeHUh?=
SK-MES-1 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfNbFBKSzVyPUCuN|I5KG6P M2C5OnNCVkeHUh?=
NCI-H1355 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwM{ixJI5O Mo\KV2FPT0WU
YKG-1 NV;YTVV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvZYFKSzVyPUCuOFE6KG6P M3[1cXNCVkeHUh?=
RS4-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LTT2lEPTB;MD60N|Mhdk1? NF31VWlUSU6JRWK=
Daoy NUTPcoxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGwWZNNUUN3ME2wMlQ2PiCwTR?= MnO3V2FPT0WU
A3-KAW Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvCTWM2OD1yLkW1NUBvVQ>? MlLpV2FPT0WU
SK-MEL-30 NYX6ToVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmflTWM2OD1yLkW1OEBvVQ>? NIHaXoNUSU6JRWK=
U031 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:2TFB5UUN3ME2wMlU3PSCwTR?= MXnTRW5ITVJ?
SK-LMS-1 NFXsN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvXTWM2OD1yLkW3PEBvVQ>? MlrFV2FPT0WU
ES6 NVjQ[m1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwNUi2JI5O M4\OUHNCVkeHUh?=
EoL-1-cell NIfybGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPjbVhOUUN3ME2wMlYyPiCwTR?= NYrZSmQ6W0GQR1XS
NCI-H2009 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP6cXNwUUN3ME2wMlYyQSCwTR?= M1PN[3NCVkeHUh?=
A4-Fuk NH;QVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr1TWM2OD1yLk[yOkBvVQ>? NYLlS5RKW0GQR1XS
KYSE-270 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnntTWM2OD1yLk[zOEBvVQ>? NHK0V4tUSU6JRWK=
SK-LU-1 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLud|ZKSzVyPUCuOlU2KG6P NXnJWIVuW0GQR1XS
SW872 NHH1T|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrad2tvUUN3ME2wMlc3PSCwTR?= MkCyV2FPT0WU
ES8 M1PXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDQ[INUUUN3ME2wMlc5KG6P NGDtfndUSU6JRWK=
G-402 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPyZW5KSzVyPUCuO|g1KG6P M1S1RnNCVkeHUh?=
ATN-1 M3\vS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULTeHZjUUN3ME2wMlgxPyCwTR?= MULTRW5ITVJ?
DoTc2-4510 NIPH[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwOUCxJI5O NWXnWFh1W0GQR1XS
MES-SA M1LYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwOUC1JI5O NFX4V4hUSU6JRWK=
SF268 M3f1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnCcYhVUUN3ME2wMlkzPyCwTR?= M4TFfXNCVkeHUh?=
SF539 M1nmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoryTWM2OD1zLkCyJI5O NVXTb4ltW0GQR1XS
NB69 M4XRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHaZZRKSzVyPUGuNFUhdk1? M1\TXnNCVkeHUh?=
8505C MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT5TWM2OD1zLkC2JI5O MV\TRW5ITVJ?
CAL-12T MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvXT2NXUUN3ME2xMlA5KG6P NYnseFV3W0GQR1XS
BHY M3TjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSycGVKSzVyPUGuNVQhdk1? NWS1c2pDW0GQR1XS
LB647-SCLC M4i0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonMTWM2OD1zLkG4JI5O NFG3Tm5USU6JRWK=
CAL-62 NEG0XHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\QTGlEPTB;MT6yNkBvVQ>? NFzlSHpUSU6JRWK=
MEG-01 NUDRXmt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwMkegcm0> M161ZnNCVkeHUh?=
MG-63 NX3aUGlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\kbXQ4UUN3ME2xMlM{KG6P MUPTRW5ITVJ?
SW620 NHfXNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS0dYRKSzVyPUGuN|Uhdk1? M3nIcnNCVkeHUh?=
A388 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TkR2lEPTB;MT6zOkBvVQ>? NFO3SXBUSU6JRWK=
BCPAP NFmwVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwNEWgcm0> MkLYV2FPT0WU
P30-OHK NFnxe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfmVHdKSzVyPUGuOFYhdk1? NHfHVlZUSU6JRWK=
Ca9-22 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwNUSgcm0> NVO3XGJWW0GQR1XS
VMRC-RCZ NEfzNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD1zLkW0JI5O MXjTRW5ITVJ?
LOXIMVI M2r6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\sTWM2OD1zLk[gcm0> NFXIXWlUSU6JRWK=
L-540 M3;KfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7BTWM2OD1zLk[gcm0> M4XSR3NCVkeHUh?=
NTERA-S-cl-D1 NFi5d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr4TWM2OD1zLk[0JI5O M2HkcnNCVkeHUh?=
MFH-ino MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwNk[gcm0> NXTTSmx2W0GQR1XS
Calu-6 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jTc2lEPTB;MT63N{BvVQ>? NGnrTlFUSU6JRWK=
HEL M2\VWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[0dnpKSzVyPUGuO|khdk1? NFTzcZRUSU6JRWK=
CAL-33 NHLFe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DxVWlEPTB;MT64PUBvVQ>? NWe2O4syW0GQR1XS
HSC-3 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwOUGgcm0> NVvOVo1TW0GQR1XS
KU812 NEjlOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwOUGgcm0> M3PybXNCVkeHUh?=
EB2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\ZTnVCUUN3ME2yMlAyKG6P Ml34V2FPT0WU
SR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwMUKgcm0> M{Dp[HNCVkeHUh?=
NCI-H2087 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS3c5JKSzVyPUKuNVQhdk1? M4TsVXNCVkeHUh?=
H4 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnOTWdKSzVyPUKuNVghdk1? MWLTRW5ITVJ?
EW-1 M2X4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L2emlEPTB;Mj6yNkBvVQ>? Ml7EV2FPT0WU
MC-IXC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnnSo15UUN3ME2yMlI3KG6P NH[2TXlUSU6JRWK=
NCI-H727 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnQ[mdSUUN3ME2yMlUyKG6P NIe0N3dUSU6JRWK=
MRK-nu-1 NHzVcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwNUegcm0> NFHJO4lUSU6JRWK=
COLO-668 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmxZpRSUUN3ME2yMlY3KG6P MoWxV2FPT0WU
CGTH-W-1 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKxblZKSzVyPUKuO|Ihdk1? NIHTW|lUSU6JRWK=
CHP-212 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjXXXlKSzVyPUKuO|Uhdk1? NUD5R5pMW0GQR1XS
GI-1 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPZcHZKSzVyPUKuO|Yhdk1? M37LO3NCVkeHUh?=
HCC1806 M1XtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyyO|ZKSzVyPUKuPVEhdk1? MVHTRW5ITVJ?
HLE NILlNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNibl2= NWXkcIRWW0GQR1XS
HSC-2 NWTjUVdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzoTWM2OD1|LkCzJI5O MUnTRW5ITVJ?
DMS-273 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PNN2lEPTB;Mz6wO{BvVQ>? MkXzV2FPT0WU
DU-4475 NEPRXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTNwMUSgcm0> MmPQV2FPT0WU
LXF-289 M3ThN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fJU2lEPTB;Mz6zNUBvVQ>? NU\QNXpbW0GQR1XS
PANC-03-27 NFP2cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHoTWM2OD1|LkWxJI5O MkLPV2FPT0WU
GAMG NFvMeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTNwN{Sgcm0> M4fRSnNCVkeHUh?=
NCI-H522 M4DyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLDTWM2OD12LkO0JI5O NVq2WFdvW0GQR1XS
SW626 MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwNE[gcm0> NFO3bWFUSU6JRWK=
HT-144 M1y1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\vemlEPTB;ND65NkBvVQ>? MlvXV2FPT0WU
MEL-HO MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVwMU[gcm0> MUnTRW5ITVJ?
BE-13 NYfRSYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTVwMkGgcm0> NVLtXGtxW0GQR1XS
VA-ES-BJ MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLGTWM2OD13LkK2JI5O NFLHOpJUSU6JRWK=
NCI-H441 NH;NfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL0WHhyUUN3ME21MlYhdk1? NGXnWGNUSU6JRWK=
KP-4 NWWyblA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml71TWM2OD13Lk[xJI5O NGrvbohUSU6JRWK=
LoVo MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLDT5lKSzVyPUWuO|Ehdk1? NH;zS5lUSU6JRWK=
HT-1080 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:3TWM2OD13LkizJI5O M3T1c3NCVkeHUh?=
GB-1 NWT2VHBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTVwOESgcm0> NX7YUYYzW0GQR1XS
IA-LM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTVwOUGgcm0> NEnGV5pUSU6JRWK=
8-MG-BA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwOUOgcm0> MVfTRW5ITVJ?
SK-HEP-1 M4i5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\CTWM2OD14LkG0JI5O MX7TRW5ITVJ?
697 NVnnNIxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\TTWM2OD14LkK1JI5O MWnTRW5ITVJ?
KYSE-450 M4fqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnziTWM2OD14LkOyJI5O M3\qdnNCVkeHUh?=
HCC2998 NGT2cVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDYUHZKSzVyPU[uN|Qhdk1? NVqwcI51W0GQR1XS
HD-MY-Z M3;WfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nxSGlEPTB;Nj62PEBvVQ>? NUCxcGp4W0GQR1XS
OS-RC-2 M{PNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;RTWM2OD14Lk[4JI5O MmnyV2FPT0WU
SF126 NXixd4xTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLzT3dRUUN3ME23MlA2KG6P NVrH[|FrW0GQR1XS
Ca-Ski NVrDNWc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H5WmlEPTB;Nz6wPUBvVQ>? MnftV2FPT0WU
NCI-H358 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPvNpBRUUN3ME23MlE3KG6P NEnGfHhUSU6JRWK=
J82 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm2c|NKSzVyPUeuOFEhdk1? NWXnfHJJW0GQR1XS
NCI-H2342 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XDUmlEPTB;Nz62N{BvVQ>? NH\Dd3hUSU6JRWK=
OVCAR-8 NUX5c|R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTdwOTDuUS=> MWLTRW5ITVJ?
TE-8 M{SxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fjcmlEPTB;ODDuUS=> MX;TRW5ITVJ?
ETK-1 NF7rWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRThwMEigcm0> MmXTV2FPT0WU
HAL-01 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT4bIVKSzVyPUiuNkBvVQ>? MVXTRW5ITVJ?
KYSE-150 NFrscGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonQTWM2OD16LkS3JI5O NI\vd3ZUSU6JRWK=
NCI-H810 NF\0NIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXiTWM2OD16LkW2JI5O Ml7WV2FPT0WU
ONS-76 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLNTWM2OD16Lk[4JI5O NYHGOYdYW0GQR1XS
NMC-G1 M1L4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRThwN{[gcm0> M32xcnNCVkeHUh?=
C3A M3;FOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3PTWM2OD16Lki0JI5O MWPTRW5ITVJ?
PA-1 NWn0Rm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jDZmlEPTB;OD65PUBvVQ>? M4DVNnNCVkeHUh?=
SH-4 M{jscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m4[mlEPTB;OT6wNkBvVQ>? MUjTRW5ITVJ?
EFO-27 NFjsVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;HTWM2OD17LkC1JI5O MVrTRW5ITVJ?
CAPAN-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTlwMkOgcm0> MnP0V2FPT0WU
DU-145 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vzOWlEPTB;OT6yPUBvVQ>? MX3TRW5ITVJ?
A101D NY\PeZJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHBTWM2OD17LkO3JI5O MnO3V2FPT0WU
ST486 NW\re2xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnCTWM2OD17LkSxJI5O NYLNfoRjW0GQR1XS
NCI-H1437 M{DKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTlwNEKgcm0> NIHK[WdUSU6JRWK=
HGC-27 NHHG[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTlwNjDuUS=> M1i1RnNCVkeHUh?=
8305C M4nmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTlwNkSgcm0> Mn\sV2FPT0WU
OCUB-M MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;aTWM2OD1zMD6wN{BvVQ>? M1\BXXNCVkeHUh?=
COLO-679 NX:wV3p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfCR3JGUUN3ME2xNE4xPyCwTR?= NYnE[JA4W0GQR1XS
Detroit562 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFyLkSyJI5O NHzaW2xUSU6JRWK=
A204 NXq0SWxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFzLkG2JI5O NWT0PXdTW0GQR1XS
NCI-H1734 NHHkSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zSbWlEPTB;MUGuNlkhdk1? MkTSV2FPT0WU
MC-CAR MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYexWWpXUUN3ME2xNU42QCCwTR?= MoTzV2FPT0WU
NCI-H2170 M4rzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFzLkm3JI5O NGfsS3ZUSU6JRWK=
NCI-SNU-5 NH6ydFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXLTWM2OD1zMj6xN{BvVQ>? M{e5W3NCVkeHUh?=
HCE-T MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD3eFZHUUN3ME2xNk41OiCwTR?= MXTTRW5ITVJ?
KYSE-180 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjiPIxKSzVyPUGyMlgyKG6P NXfYS3lCW0GQR1XS
C8166 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH4TWM2OD1zMz6wPEBvVQ>? M1XvU3NCVkeHUh?=
NCI-H460 NWPCSnZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO1RoVKSzVyPUGzMlU1KG6P NGW2XYZUSU6JRWK=
SNU-449 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLCNlVKSzVyPUGzMlc4KG6P MUjTRW5ITVJ?
MDA-MB-468 M1Lhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF2LkGyJI5O NH;mOmRUSU6JRWK=
COR-L23 NUL3VG5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLUW|RKSzVyPUG0MlE{KG6P NV7FOWdJW0GQR1XS
CTV-1 M1n6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnI[GxYUUN3ME2xOE4yPCCwTR?= NVPzXY93W0GQR1XS
BL-41 NWniTGVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP0TWM2OD1zND6zO{BvVQ>? M13pSXNCVkeHUh?=
IGR-1 NG\YW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF2LkSyJI5O NILk[5JUSU6JRWK=
TK10 NHjZSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nT[2lEPTB;MUSuOFkhdk1? MnX4V2FPT0WU
REH M1vId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF2LkWxJI5O NHXMTYFUSU6JRWK=
LU-139 NITiUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnxVpFuUUN3ME2xOE42QSCwTR?= NWrIToR2W0GQR1XS
KP-N-YS NX3vTZVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF2Lkm3JI5O NVfaUJBKW0GQR1XS
PANC-10-05 NX;3XpdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzB[2VOUUN3ME2xOU4{QCCwTR?= NF7h[4hUSU6JRWK=
HL-60 NFzQSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzuTWM2OD1zNT62PUBvVQ>? MYLTRW5ITVJ?
T84 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1TWM2OD1zNT65OkBvVQ>? MmXwV2FPT0WU
RPMI-8226 NFnoTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF4LkCyJI5O M3PnZXNCVkeHUh?=
UM-UC-3 NIHScYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXLXJNKSzVyPUG2MlE3KG6P NWS4PXc2W0GQR1XS
TE-10 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ra[mlEPTB;MU[uNlEhdk1? MkjWV2FPT0WU
CAL-148 NYHVXmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF5LkKzJI5O M4DzT3NCVkeHUh?=
BV-173 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7GTWM2OD1zNz6yO{BvVQ>? NILWZ41USU6JRWK=
Calu-3 NU\mNZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD1zNz6yPUBvVQ>? NIj2S2tUSU6JRWK=
RPMI-2650 M1\JPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnrUmZKSzVyPUG3MlU6KG6P M{DNZ3NCVkeHUh?=
MKN45 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF5LkezJI5O MnOzV2FPT0WU
NUGC-3 M1P3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rsS2lEPTB;MUiuN|Qhdk1? MmLGV2FPT0WU
NCI-H520 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\3UXFOUUN3ME2xPE44PyCwTR?= MX7TRW5ITVJ?
CCRF-CEM M4rXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnjTWM2OD1zOD64OUBvVQ>? MoXBV2FPT0WU
NCI-H2405 NX74WFd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfnR5JiUUN3ME2xPU4yKG6P M4\T[XNCVkeHUh?=
ES7 M2LBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv2TWM2OD1zOT63OkBvVQ>? M2K5VnNCVkeHUh?=
BPH-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJyLkK4JI5O MYrTRW5ITVJ?
SAS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXHPHhKSzVyPUKwMlUhdk1? MWnTRW5ITVJ?
HuCCT1 NYn0fml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HXc2lEPTB;MkCuOVghdk1? NF7HRXFUSU6JRWK=
LOUCY NIC0TVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJyLk[2JI5O M4C5TXNCVkeHUh?=
NCI-H292 M2fEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XKXWlEPTB;MkCuO|khdk1? NHfGflRUSU6JRWK=
G-361 M1LzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLse4lKSzVyPUKxMlA4KG6P NVmyTHJnW0GQR1XS
M059J NWfiZZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCxTWM2OD1{MT6wPEBvVQ>? MYHTRW5ITVJ?
NCI-H1651 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH1VnFKSzVyPUKxMlEyKG6P MYHTRW5ITVJ?
KALS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Ob5loUUN3ME2yNU4{QSCwTR?= MmTPV2FPT0WU
DJM-1 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojUTWM2OD1{MT61PUBvVQ>? NEfxWIVUSU6JRWK=
AU565 NWnSbmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL3PIJHUUN3ME2yNU45OyCwTR?= NXjxZldRW0GQR1XS
HCC38 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnXc|JwUUN3ME2yNU46PSCwTR?= NVTZWmh[W0GQR1XS
U251 NHH3VFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GybGlEPTB;MkKuNlchdk1? M1XqbXNCVkeHUh?=
ABC-1 NFP1dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvzXolKSzVyPUKyMlY2KG6P MXLTRW5ITVJ?
SK-NEP-1 NFHpW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzJXHlKSzVyPUKyMlk{KG6P NF7OToVUSU6JRWK=
CESS NHTWW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e2WmlEPTB;MkOuNVkhdk1? MXXTRW5ITVJ?
MIA-PaCa-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjoO4dKSzVyPUKzMlM3KG6P MWXTRW5ITVJ?
SUP-T1 NUTXVFhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjrWZZzUUN3ME2yN{41PyCwTR?= NHv5cFFUSU6JRWK=
L-428 M17id2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ|Lk[yJI5O NEfGbGtUSU6JRWK=
SW954 NFfVeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorxTWM2OD1{Mz62PEBvVQ>? MYXTRW5ITVJ?
HO-1-N-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUezToJ1UUN3ME2yN{44PyCwTR?= MnfIV2FPT0WU
CHP-126 NVTnfplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\MTWlEPTB;MkSuNVQhdk1? NYjQUmVbW0GQR1XS
HMV-II MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rsZmlEPTB;MkSuN|Qhdk1? MVTTRW5ITVJ?
NB10 NHy4XFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX2TWM2OD1{ND6zO{BvVQ>? NHThXJNUSU6JRWK=
A172 NUjMNmdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ2LkexJI5O NXnjeVRQW0GQR1XS
MONO-MAC-6 NV;1enpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXwepFKSzVyPUK0Mlg1KG6P NX2ycY5SW0GQR1XS
NCI-H1650 NHXWTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LzNGlEPTB;MkWuOEBvVQ>? MofLV2FPT0WU
NH-12 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ3LkWgcm0> MWHTRW5ITVJ?
ML-2 M2DUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXFTWM2OD1{NT63OEBvVQ>? M{nSOHNCVkeHUh?=
MZ2-MEL NXuxdlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDMe2dKSzVyPUK2MlIzKG6P M3;ZXnNCVkeHUh?=
COLO-684 NH;TUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XpZmlEPTB;Mk[uOFEhdk1? NXjwcG1qW0GQR1XS
HuP-T4 M2PHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ5LkOgcm0> M{my[HNCVkeHUh?=
SW837 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HZ[WlEPTB;MkeuOlIhdk1? NIr6[lRUSU6JRWK=
MDA-MB-231 NEmwSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXYNmhXUUN3ME2yO{44QCCwTR?= Mn61V2FPT0WU
KYSE-140 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPfIlKSzVyPUK3MlkyKG6P M1e1[nNCVkeHUh?=
NOMO-1 NHzpZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LTT2lEPTB;MkiuOlghdk1? NVHQPYRIW0GQR1XS
GP5d MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\nPGlEPTB;MkiuO|Ihdk1? MkX2V2FPT0WU
COR-L105 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVznV|M1UUN3ME2yPU41OiCwTR?= M2\lUHNCVkeHUh?=
LS-411N NVzPfohXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL4TWM2OD1{OT64PEBvVQ>? NEnhUpFUSU6JRWK=
NY M4PCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfNbmxIUUN3ME2zNE4yQCCwTR?= M3u1cHNCVkeHUh?=
NCI-H2030 M{Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXITWM2OD1|MD60OUBvVQ>? NW\Uc2tnW0GQR1XS
CCF-STTG1 NXPK[WxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnzTWM2OD1|MT60NkBvVQ>? NFTKXZJUSU6JRWK=
NCI-H1703 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0TWM2OD1|MT63PEBvVQ>? NHfhbolUSU6JRWK=
TUR MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTCboI6UUN3ME2zNk4xOyCwTR?= MojLV2FPT0WU
NOS-1 NWjvdoZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3Ne2FKSzVyPUOyMlQ1KG6P NHTyNWJUSU6JRWK=
A2058 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXPO5RUUUN3ME2zNk45OyCwTR?= NYTh[FBHW0GQR1XS
LCLC-103H MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTN|LkK1JI5O M2DDVXNCVkeHUh?=
NCI-H510A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i3W2lEPTB;M{OuNlchdk1? NWjlfYVSW0GQR1XS
BC-1 NXHxcGQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN|Lke3JI5O MXnTRW5ITVJ?
SK-CO-1 NILvd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjSOlN1UUN3ME2zOE4xOSCwTR?= MkS4V2FPT0WU
A673 NUPlU45rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITKUlZKSzVyPUO0MlE4KG6P NXviepFvW0GQR1XS
VM-CUB-1 NE\hWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LjUGlEPTB;M{SuOlkhdk1? NWCz[Y4yW0GQR1XS
HH NWniXm1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHTZY5KSzVyPUO1MlA3KG6P M1joOXNCVkeHUh?=
CAL-27 M1TkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXNUnRKSzVyPUO1MlE3KG6P MXfTRW5ITVJ?
NEC8 MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vhS2lEPTB;M{WuN|chdk1? MWfTRW5ITVJ?
BxPC-3 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN4LkmxJI5O Ml:wV2FPT0WU
SNB75 NFvMcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1[GlEPTB;M{euNlQhdk1? MoC3V2FPT0WU
NB13 M{LCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN6LkKzJI5O MnzHV2FPT0WU
SK-OV-3 NXTPfVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP3TWM2OD1|OD63OEBvVQ>? MYDTRW5ITVJ?
ME-180 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTN6Lkigcm0> M4XpZXNCVkeHUh?=
JiyoyeP-2003 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[4ellkUUN3ME2zPU4{QCCwTR?= MWrTRW5ITVJ?
LU-134-A NVLZWGRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWwT25xUUN3ME20NE4xOiCwTR?= MnTpV2FPT0WU
LS-123 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33nPGlEPTB;NECuNlghdk1? Mn\LV2FPT0WU
COLO-800 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW0XmdKSzVyPUSwMlU3KG6P NHPPXm9USU6JRWK=
LB831-BLC MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTrTWM2OD12MT64OUBvVQ>? NX7SbYZqW0GQR1XS
NCI-H747 M1fZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzqUnFZUUN3ME20Nk4zQCCwTR?= M{jtUnNCVkeHUh?=
MZ7-mel MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrlNHpKSzVyPUSyMlY3KG6P M{TJcXNCVkeHUh?=
GT3TKB NX3COpJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\FW|FKSzVyPUSyMlczKG6P M3LORnNCVkeHUh?=
MOLT-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHvTWM2OD12Mz6wOUBvVQ>? NWPDcFBmW0GQR1XS
23132-87 NVTLWJBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7rdlIxUUN3ME20N{4xPSCwTR?= MWDTRW5ITVJ?
PF-382 M4PhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zoNGlEPTB;NESuNlIhdk1? NYTaPG9sW0GQR1XS
ES3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR2Lk[gcm0> MmXhV2FPT0WU
SW756 NWHre4I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37IcmlEPTB;NEWuNVQhdk1? NYrpfFhXW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α ; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control.

PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; 

PubMed: 24409315     


AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. 

27765914 24409315
Immunofluorescence
Bim1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.

27177084
Growth inhibition assay
Cell viability; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. 

27765914
In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03865563 Not yet recruiting Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1
NCT03697564 Not yet recruiting Pancreatic Cancer Stage IV Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California San Diego July 2019 Phase 2
NCT03865563 Not yet recruiting Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1
NCT03697564 Not yet recruiting Pancreatic Cancer Stage IV Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California San Diego July 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID